NeoGenomics, Inc. Increase (Decrease) in Accrued Liabilities
NeoGenomics, Inc. (NEO) reported Increase (Decrease) in Accrued Liabilities of $8.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-07-28
- NeoGenomics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $15.69M, a 82.07% increase year-over-year.
- NeoGenomics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$7.00M.
- NeoGenomics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$4.10M, a 139.87% decline year-over-year.
- NeoGenomics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $2.77M, a 115.80% increase year-over-year.
- NeoGenomics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$15.66M, a 268.75% decline from fiscal 2024.
- NeoGenomics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $9.28M, a 28.70% decline from fiscal 2023.
- NeoGenomics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $13.02M, a 608.76% increase from fiscal 2022.
- NeoGenomics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $1.84M, a 84.18% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | $8.69M 10-Q · filed 2026-07-28 | $4.59M derived: sum of 3 quarters · filed 2026-07-28 | $7.36M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | -$7.00M 10-Q · filed 2026-04-28 | -$11.10M derived: sum of 2 quarters · filed 2026-04-28 | -$8.33M derived: sum of 3 quarters · filed 2026-04-28 | $288.00K derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | -$4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$1.32M derived: sum of 2 quarters · filed 2026-02-17 | $7.29M derived: sum of 3 quarters · filed 2026-07-28 | -$15.66M 10-K · filed 2026-02-17 |
| 2025-09-30 | $2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $11.39M derived: sum of 2 quarters · filed 2026-07-28 | -$11.57M 10-Q · filed 2025-10-28 | -$1.29M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | $8.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | -$14.34M 10-Q · filed 2026-07-28 | -$4.06M derived: sum of 3 quarters · filed 2026-07-28 | -$2.78M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | -$22.96M 10-Q · filed 2026-04-28 | -$12.68M derived: sum of 2 quarters · filed 2026-04-28 | -$11.39M derived: sum of 3 quarters · filed 2026-04-28 | $4.88M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $10.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $11.56M derived: sum of 2 quarters · filed 2026-02-17 | $27.84M derived: sum of 3 quarters · filed 2026-02-17 | $9.28M 10-K · filed 2026-02-17 |
| 2024-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $17.56M derived: sum of 2 quarters · filed 2025-10-28 | -$996.00K 10-Q · filed 2025-10-28 | $4.57M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $16.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$2.28M 10-Q · filed 2025-07-29 | $3.29M derived: sum of 3 quarters · filed 2026-02-17 | $5.19M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | -$18.55M 10-Q · filed 2025-04-29 | -$12.98M derived: sum of 2 quarters · filed 2026-02-17 | -$11.08M derived: sum of 3 quarters · filed 2026-02-17 | $1.72M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $5.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $7.47M derived: sum of 2 quarters · filed 2026-02-17 | $20.27M derived: sum of 3 quarters · filed 2026-02-17 | $13.02M 10-K · filed 2026-02-17 |
| 2023-09-30 | $1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $14.70M derived: sum of 2 quarters · filed 2024-11-05 | $7.45M 10-Q · filed 2024-11-05 | $9.60M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $12.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $5.54M 10-Q · filed 2024-07-30 | $7.70M derived: sum of 3 quarters · filed 2025-02-18 | $8.41M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | -$7.25M 10-Q · filed 2024-04-30 | -$5.10M derived: sum of 2 quarters · filed 2025-02-18 | -$4.39M derived: sum of 3 quarters · filed 2025-02-18 | $572.00K derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $2.86M derived: sum of 2 quarters · filed 2025-02-18 | $7.82M derived: sum of 3 quarters · filed 2025-02-18 | $1.84M 10-K · filed 2025-02-18 |
| 2022-09-30 | $711.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $5.67M derived: sum of 2 quarters · filed 2023-11-06 | -$313.00K 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $4.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.02M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$5.99M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | $11.61M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |